2017 Program: 5th Update on Fabry Nephropathy:
Biomarkers, Progression and Treatment Opportunities

April 25-27, 2017: Mexico City DF, Mexico

An Official Satellite of the WCN (Mexico City)
Supporting Organization: Kidneys for Life (Manchester, UK)
http://kidneysforlife.org/

Program Co-Chairs
Ricardo Correa-Rotter, Instituto Nacional de Ciencias Médicas y Nutrición
Salvador Zubirán, Mexico City
Derralyn Hughes, Royal Free Hospital, London UK
Gregorio T. Obrador, Panamericana School of Medicine, Mexico City
Luiz Antonio Ribeiro Moura, Federal University of Sao Paulo, Brazil
Juan M Politei, FESN Buenos Aires, Argentina
Raphael Schiffmann, Baylor Research Institute, Dallas TX USA
Hernán Trimarchi, Hospital Britanico de Buenos Aires, Argentina
Stephen Waldek, Manchester UK
Christoph Wanner, University of Wurzburg, Wurzburg Germany
David G. Warnock, University of Alabama at Birmingham, USA
Michael West, Dalhousie University, Nova Scotia, Canada

This educational activity is supported by unrestricted medical education grants from:
Actelion Pharmaceuticals, Ltd; Amicus Therapeutics; Protalix Biotherapeutics; others pending
CONFIRMED PROGRAM

Tuesday April 25, 2017:

12:00 pm  Onsite Registration

Opening Session
3:00  Ricardo Correa-Rotter and Gregorio Obrador: Welcome
3:15  Introduction of Keynote Speakers and Stage of the Art Lectures – Rafael Schiffmann (USA) and David Warnock (USA)
3:35 – 4:30  Tobias Huber (Germany): Fabry Disease, from Drosophila to Rats to Humans
4:30 – 5:15  Christoph Wanner (Germany): Classic and Non-Classic Fabry Disease
5:15 – 6:00  Giuseppe Remuzzi (Italy); Progression of Proteinuric CKD: Lessons for Fabry Nephropathy
6:00 – 8:30  Poster Sessions and Opening Reception

Wednesday April 26, 2017: Mexico City DF

8:30  Phenotypic Variation in Fabry Disease; Chairs: Stephen Waldek (UK) and David Warnock (USA)
8:30 – 9:05  Phenotypic Variation and Mutation Analysis: João Paulo Oliveira (Portugal)
9:05 – 9:40  Phenotypic Variation in Alport’s Syndrome: Roser Torra-Balcells (Spain)
9:40 – 10:15  Phenotypic Variation with the IVS4+919G Variant: Dau-Ming Niu (Taiwan)
10:15 – 10:45  Females and Fabry Disease: Dominique Germain (France)
10:45 – 11:15  Coffee Break
11:15 – 12:30  Moderated Discussion on Histologic Assessment of Fabry Nephropathy; Chairs: Luiz A. Moura (Brazil) and Agnes Fogo (USA)
11:15 – 11:30  Biopsies from Children with Fabry Disease; Lessons Learned and Unanswered Questions: Camilla Tøndel (Norway)
11:30 – 12:15  Discussion Participants: Laura Barisoni (USA), Randy Hennegar (USA), Robert Hopkin (USA), Behzad Najafian (USA)
12:15 – 12:30  Summary and Conclusions; Agnes Fogo (USA) and Luiz A. Moura (Brazil)
12:30 – 14:00  Working Lunch and Poster Viewing
14:00  Molecular Mechanisms in Fabry Disease: Chairs, Alberto Ortiz (Spain), and James Shayman (USA)
14:00 – 14:45  Structural Basis for Inhibition of alpha-galactosidase A: Scott Garman
14:45 – 15:15  Lyso-Gb3 and Analogues in Cardiac Variant Mutations: Christiane Auray-Blais
15:15 – 15:45  Vascular and Cardiac Hypertrophy in Fabry Disease: Peter McCullough
15:45 – 16:15  Coffee Break
16:15  Cellular Injury and Responses: Chairs, Camilla Tøndel (Norway) and Suichi Ito (Japan)
16:15 – 16:45  Molecular Mechanisms of Podocyte Injury: M. D. Sanchez Niño (Spain)
16:45 – 17:15  Podocyturia: Hernán Trimarchi (Argentina)
17:15 – 17:45  Podocyte Biomarkers and Response to ERT: Kevin Mills (UK)
17:45 – 18:45  Oral Presentations from Poster Sessions; Chairs: Hernán Trimarchi (Argentina) and Kathy Nicholls (Australia). The top 5 posters will be presented as 8 min presentations with 3 minutes for questions. Poster Selection Committee: Hugo Abensur (Brazil); Ricardo Correa-Rotter (Mexico); Giovanni Duro (Italy); Luis E. Figueroa (Mexico); Dominique Germain (France); Richard J. Glassock (US); Ana Maria Martins (Brazil); Ichiel Narita (Japan); Gregorio Obrador (Mexico); Juan Politei (Argentina); Andrew Talbot (Australia)

Wednesday Evening: Fiesta (on site)
Thursday April 27, 2017

8:00 Immune Responses to ERT; Chairs: Robert Hopkin (USA) and Christoph Wanner (Germany)
8:00 – 8:25 Clinical Significance of Antibodies: Malte Lenders (Germany)
8:25 – 8:50 Secondary Membranous Nephropathy and ERT: Pierre Ronco (France)
8:50 – 9:15 Predicting Immunogenicity from Genotype, Lessons from Pompe Disease: Deeksha Bali (USA)
9:15 – 9:40 Immune Modulation with Bortezomib: Derralyn Hughes (UK)
9:40 – 10:00 Discussion
10:00 – 10:20 Coffee Break

10:20 New Therapeutic Approaches; Chairs: Yoshi Eto (Japan) and Michael West (Canada)
10:20 – 10:45 Substrate Reduction Therapy: Past, Present and Future: James Shayman (USA)
10:45– 11:10 Extending the Range of “Amenable Mutations”: Elfrida Benjamin (Amicus)
11:10 – 11:35 Immunogenicity and Pharmacokinetics of PegUNIGALsidas: Einat Almon (Protalix)
11:35 – 12:00 Gene Therapy Approaches, Jeffery Medin (USA)

12:00 –12:45 Debate: Lyso-GB3(s) – Fit for What Purpose(s); Moderators: Christiana Auray-Blais (Canada) and Christoph Wanner (Germany)
Con: Raphael Schiffmann (USA)
Pro: Derralyn Hughes (UK)

12:45 –13:00 Announcements: Poster Prize Winners; Hernán Trimarchi (Argentina) and Kathy Nicholls (Australia)

13:00 Optional Buffet Lunch and Departures